Assays for the qualitative or semi-quantitative analysis of amphetamines or methylenedioxymethamphetamine (MDMA) and closely related drugs (MDEA and MDA) in human urine
Olympus has announced the availability of two new Emit II Plus assays: Amphetamines (OSR9C229) and Ecstasy (OSR9X229).
The assays expand the drugs of abuse (DOA) testing capabilities of the entire Olympus AU chemistry-immuno analyser system platform, including the AU400/400e, AU600, AU640/640e, AU2700 and AU5400 chemistry-immuno analysers.
The Emit II Plus Amphetamines and Ecstasy assays come in a liquid, ready-to-use format with 30-day on-board stability and are OSR bar-coded for convenient reagent management.
Specific calibrator cutoffs are provided in accordance with proposed Samhsa guidelines.
The Emit family of assays is widely recognised for excellence in drug diagnostic testing, says Olympus.
The Emit II Plus Amphetamines assay is a homogeneous enzyme immunoassay with cutoff levels at 300ng/ml, 500ng/ml, or 1000ng/ml.
The new Amphetamine antibody, d-meth and d-amph equivalent, enables greater separation, improved low-end sensitivity and a greater assay range (150-2000ng/ml).
The assay is intended for the qualitative or semi-quantitative analysis of amphetamines in human urine.
The Emit II Plus Ecstasy assay is a homogeneous enzyme immunoassay with cutoff levels at 300ng/ml or 500ng/ml.
The assay is intended for the qualitative or semi-quantitative analysis of methylenedioxymethamphetamine (MDMA) and closely related drugs (MDEA and MDA) in human urine.
The Ecstasy assay can be used alone or in conjunction with the new Amphetamines assay.
